Ruby Leong

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma”.

FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1272

N/A

1.4DataRank · unranked

35 citations

Yvette L. Kasamon, Justin S. Collazo, Ruby Leong, Kun Wang, P Li +8 more

FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4525

N/A

0DataRank · unranked

25 citations

Xin Wang, Meng Li, Hongshan Li, Shwu‐Luan Lee, Nina Ni +9 more

FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0688

N/A

0DataRank · unranked

3 citations

Donna R. Rivera, Joseph Wynne, Jian Zhao, Robyn Konicki, Aida Kuzucan +8 more